*Actual product packaging may differ from the image shown.
AOD-9604 / MOTS-C / Tesamorelin
AOD-9604 / MOTS-c / Tesamorelin is a comprehensive metabolic and body-composition peptide combination designed to support fat loss, mitochondrial energy production, and healthy growth hormone signaling. AOD-9604 promotes fat breakdown and limits new fat storage, MOTS-c enhances cellular energy and metabolic flexibility, and Tesamorelin stimulates the body’s natural growth hormone release, supporting fat metabolism, lean mass, and overall metabolic health. Together, this combination offers a more robust approach to body recomposition and long-term metabolic optimization than any single peptide alone.
Protocols developed under the clinical direction of Dr. Jonathann Kuo, MD
Select Size:
What happens after checkout
- ①Purchase your treatment
- ②Complete your Qualiphy consultation via email (~3 min)
- ③Licensed provider reviews & approves your prescription
- ④Pharmacy ships within 3–5 days of approval
After checkout, you'll receive an email to complete your telehealth consultation. A licensed provider must approve before your order ships.
Potential benefits may include:
- Promotes fat loss by increasing lipolysis and reducing fat storage
- Supports mitochondrial function and cellular energy production
- Enhances metabolic efficiency and flexibility
- Stimulates natural growth hormone release without direct GH administration
- Helps preserve or support lean muscle mass
- Improves energy, recovery, and exercise tolerance
- Complements nutrition, movement, and other metabolic or peptide therapies
- Pregnancy or Breastfeeding: Safety has not been established; use is not recommended.
- Active Cancer or Recent Cancer Treatment: Growth hormone–pathway and metabolic peptides are generally avoided.
- Known Allergy: Avoid use if you have a sensitivity to peptide-based therapies or formulation components.
- Severe Liver, Kidney or Endocrine Disorders: Should be used only under medical supervision.
AOD-9604 / MOTS-c / Tesamorelin is generally well tolerated when used under medical supervision. Mild, short-term effects may occasionally occur, especially when first starting or adjusting dose, including:
- Temporary redness, tenderness, or itching at the injection site
- Mild headache or light fatigue as metabolic and hormonal signaling adjusts
- Temporary changes in appetite or digestion
- Brief muscle warmth or mild flushing (more commonly associated with MOTS-c)
- Mild water retention or bloating (more commonly associated with Tesamorelin)
These effects are typically mild and resolve as the body adapts.
For safe and informed use, review the Extension Health Injection Reaction Guide (PDF), which outlines what to expect, how to reduce discomfort, and when to seek medical support.
- Weeks 1–2: AOD-9604 begins signaling fat cells to increase fat breakdown (lipolysis) and reduce new fat storage, while MOTS-c starts supporting mitochondrial energy production and metabolic flexibility. Tesamorelin initiates stimulation of the body’s natural growth hormone release, primarily affecting metabolic and hormonal signaling rather than visible changes. Early effects are largely cellular, though some patients notice subtle shifts in energy, appetite awareness, or sleep quality.
- Weeks 3–6: As metabolic, mitochondrial, and growth hormone signaling become more consistent, the body becomes more efficient at utilizing fat and glucose for fuel. Patients may begin to notice gradual improvements in body composition, exercise recovery, and energy levels—especially when paired with nutrition, resistance training, and adequate sleep.
- Weeks 8–12: Sustained use supports ongoing fat utilization, mitochondrial efficiency, and healthy growth hormone patterns. Visible improvements in body composition, weight stability, recovery, and metabolic resilience are more likely during this phase. Results tend to be steady and sustainable, making this combination well suited for long-term metabolic optimization, body recomposition, and performance support rather than rapid weight loss.